Symbols / CARM
CARM Chart
About
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.92M |
| Enterprise Value | -90.13K | Income | 8.04M | Sales | 52.63M |
| Book/sh | -0.02 | Cash/sh | 0.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | 0.24 | Forward P/E | -0.05 | PEG | — |
| P/S | 0.04 | P/B | -2.19 | P/C | — |
| EV/EBITDA | -0.01 | EV/Sales | -0.00 | Quick Ratio | 0.65 |
| Current Ratio | 0.86 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.19 | EPS next Y | -0.91 | EPS Growth | — |
| Revenue Growth | 12.37% | Earnings | 2025-08-07 16:00 | ROA | 33.03% |
| ROE | — | ROIC | — | Gross Margin | 48.03% |
| Oper. Margin | 96.83% | Profit Margin | 15.28% | Shs Outstand | 41.85M |
| Shs Float | 30.14M | Short Float | 3.57% | Short Ratio | 0.06 |
| Short Interest | — | 52W High | 1.27 | 52W Low | 0.03 |
| Beta | 3.70 | Avg Volume | 263.45K | Volume | 5.50K |
| Target Price | — | Recom | None | Prev Close | $0.05 |
| Price | $0.05 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.05
Latest analyst target
3. DCF / Fair value
$5.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.05
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-08 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-01-17 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-01-13 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-12-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-12-12 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-12-12 | down | Baird | Outperform → Neutral | $1 |
| 2024-12-11 | down | Evercore ISI Group | Outperform → In-Line | $1 |
| 2024-12-10 | down | BTIG | Buy → Neutral | — |
| 2024-12-09 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-11-25 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-18 | main | D. Boral Capital | Buy → Buy | $24 |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $24 |
| 2024-11-07 | main | EF Hutton | Buy → Buy | $24 |
| 2024-10-30 | init | EF Hutton | — → Buy | $24 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-11 | init | BTIG | — → Buy | $6 |
- Carisma Therapeutics (CARM) to leave Nasdaq, deregister as it winds down operations - Stock Titan Fri, 05 Dec 2025 08
- $CARM stock is down 42% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Oct 2025 07
- Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com Fri, 10 Oct 2025 07
- CARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders - Business Wire Mon, 23 Jun 2025 07
- Carisma Announces Delisting from Nasdaq and SEC Deregistration - PR Newswire Fri, 05 Dec 2025 08
- Can CARISMA Therapeutics Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- Why Is Carisma Therapeutics Stock (CARM) Up 165% Today? - TipRanks ue, 02 Sep 2025 07
- Carmila (ENXTPA:CARM): Evaluating Valuation Opportunities After Recent Modest Share Price Moves - Yahoo Finance Mon, 17 Nov 2025 08
- Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 02 Sep 2025 07
- Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st Fri, 28 Mar 2025 07
- Investor Spotlight: PNPNF, CARM, RAYA, WAI, CYCU Mag Penny Undercard – More Stocks Inside - FinancialContent ue, 02 Sep 2025 07
- Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker’s Rally? - TipRanks ue, 10 Jun 2025 07
- Carisma Therapeutics stock soars after merger agreement with Ocugen - Investing.com ue, 02 Sep 2025 07
- Carisma Therapeutics Provides Corporate Updates - PR Newswire Mon, 31 Mar 2025 07
- Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension - TipRanks hu, 09 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 56982 | 14485 | — | Sale at price 0.25 per share. | KLICHINSKY MICHAEL | Officer | — | 2025-10-07 00:00:00 | D |
| 1 | 56982 | 6268 | — | Conversion of Exercise of derivative security at price 0.11 per share. | KLICHINSKY MICHAEL | Officer | — | 2025-10-07 00:00:00 | D |
| 2 | 484347 | 124343 | — | Sale at price 0.25 - 0.26 per share. | KLICHINSKY MICHAEL | Officer | — | 2025-10-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -58.83M | -85.81M | -54.27M | -40.11M |
| TotalUnusualItems | -84.00K | -1.92M | ||
| TotalUnusualItemsExcludingGoodwill | -84.00K | -1.92M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -60.48M | -86.88M | -61.23M | -40.78M |
| ReconciledDepreciation | 3.35M | 2.84M | 1.89M | 682.00K |
| EBITDA | -58.83M | -85.89M | -56.19M | -40.11M |
| EBIT | -62.18M | -88.73M | -58.08M | -40.79M |
| NetInterestIncome | 1.70M | 1.94M | -3.15M | 10.00K |
| InterestExpense | 3.15M | |||
| InterestIncome | 1.70M | 1.94M | 10.00K | |
| NormalizedIncome | -60.48M | -86.80M | -59.31M | -40.78M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -60.48M | -86.88M | -61.23M | -40.78M |
| TotalExpenses | 81.81M | 103.65M | 66.00M | 40.79M |
| TotalOperatingIncomeAsReported | -62.18M | -88.73M | -56.16M | -40.79M |
| DilutedAverageShares | 41.46M | 33.52M | 40.25M | 40.25M |
| BasicAverageShares | 41.46M | 33.52M | 40.25M | 40.25M |
| DilutedEPS | -1.46 | -2.59 | -1.52 | -1.01 |
| BasicEPS | -1.46 | -2.59 | -1.52 | -1.01 |
| DilutedNIAvailtoComStockholders | -60.48M | -86.88M | -61.23M | -40.78M |
| NetIncomeCommonStockholders | -60.48M | -86.88M | -61.23M | -40.78M |
| NetIncome | -60.48M | -86.88M | -61.23M | -40.78M |
| NetIncomeIncludingNoncontrollingInterests | -60.48M | -86.88M | -61.23M | -40.78M |
| NetIncomeContinuousOperations | -60.48M | -86.88M | -61.23M | -40.78M |
| PretaxIncome | -60.48M | -86.88M | -61.23M | -40.78M |
| OtherIncomeExpense | -84.00K | -1.92M | ||
| GainOnSaleOfSecurity | -84.00K | -1.92M | ||
| NetNonOperatingInterestIncomeExpense | 1.70M | 1.94M | -3.15M | 10.00K |
| InterestExpenseNonOperating | 3.15M | |||
| InterestIncomeNonOperating | 1.70M | 1.94M | 10.00K | |
| OperatingIncome | -62.18M | -88.73M | -56.16M | -40.79M |
| OperatingExpense | 81.81M | 103.65M | 66.00M | 40.79M |
| ResearchAndDevelopment | 59.67M | 74.12M | 56.62M | 34.39M |
| SellingGeneralAndAdministration | 22.14M | 29.52M | 9.38M | 6.41M |
| GeneralAndAdministrativeExpense | 22.14M | 29.52M | 9.38M | 6.41M |
| OtherGandA | 11.04M | 15.96M | 5.77M | 3.96M |
| InsuranceAndClaims | 1.35M | 2.89M | 211.00K | |
| SalariesAndWages | 9.75M | 10.67M | 3.40M | 2.45M |
| TotalRevenue | 19.63M | 14.92M | 9.83M | 0.00 |
| OperatingRevenue | 19.63M | 14.92M | 9.83M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 41.75M | 40.61M | 40.25M | 40.25M |
| ShareIssued | 41.75M | 40.61M | 40.25M | 40.25M |
| NetDebt | 9.52M | |||
| TotalDebt | 2.48M | 3.12M | 40.16M | 2.63M |
| TangibleBookValue | -27.91M | 26.53M | -157.06M | -96.18M |
| InvestedCapital | -27.91M | 26.53M | -123.35M | -96.18M |
| WorkingCapital | 7.77M | 64.56M | 34.92M | 22.09M |
| NetTangibleAssets | -27.91M | 26.53M | -157.06M | 11.63M |
| CapitalLeaseObligations | 2.48M | 3.12M | 6.45M | 2.63M |
| CommonStockEquity | -27.91M | 26.53M | -157.06M | -96.18M |
| PreferredStockEquity | 107.81M | |||
| TotalCapitalization | -27.91M | 26.53M | -123.35M | 11.63M |
| TotalEquityGrossMinorityInterest | -27.91M | 26.53M | -142.67M | 26.02M |
| MinorityInterest | 0.00 | 14.39M | 14.39M | |
| StockholdersEquity | -27.91M | 26.53M | -157.06M | 11.63M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -41.00K | ||
| OtherEquityAdjustments | -41.00K | |||
| RetainedEarnings | -305.58M | -245.10M | -158.22M | -97.00M |
| AdditionalPaidInCapital | 277.63M | 271.59M | 1.20M | 818.00K |
| CapitalStock | 41.00K | 40.00K | 2.00K | 107.81M |
| CommonStock | 41.00K | 40.00K | 2.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 107.81M |
| TotalLiabilitiesNetMinorityInterest | 58.37M | 63.02M | 214.82M | 9.43M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.31M | 47.11M | 195.15M | 1.73M |
| OtherNonCurrentLiabilities | 318.00K | 926.00K | 1.04M | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 107.81M | ||
| DerivativeProductLiabilities | 0.00 | 5.74M | ||
| NonCurrentDeferredLiabilities | 41.25M | 45.00M | 45.00M | |
| NonCurrentDeferredRevenue | 41.25M | 45.00M | 45.00M | |
| LongTermDebtAndCapitalLeaseObligation | 744.00K | 1.19M | 35.56M | 1.73M |
| LongTermCapitalLeaseObligation | 744.00K | 1.19M | 1.85M | 1.73M |
| LongTermDebt | 33.72M | |||
| CurrentLiabilities | 16.05M | 15.91M | 19.67M | 7.69M |
| OtherCurrentLiabilities | 1.06M | 965.00K | 523.00K | |
| CurrentDeferredLiabilities | 3.73M | 1.41M | 2.46M | |
| CurrentDeferredRevenue | 3.73M | 1.41M | 2.46M | |
| CurrentDebtAndCapitalLeaseObligation | 1.74M | 1.94M | 4.60M | 898.00K |
| CurrentCapitalLeaseObligation | 1.74M | 1.94M | 4.60M | 898.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.88M | 3.10M | 2.81M | |
| PayablesAndAccruedExpenses | 4.65M | 8.49M | 9.28M | 6.79M |
| CurrentAccruedExpenses | 2.57M | 4.56M | 7.55M | 4.47M |
| InterestPayable | 0.00 | 1.13M | ||
| Payables | 2.08M | 3.93M | 1.73M | 2.32M |
| AccountsPayable | 2.08M | 3.93M | 1.73M | 2.32M |
| TotalAssets | 30.46M | 89.55M | 72.15M | 35.45M |
| TotalNonCurrentAssets | 6.63M | 9.08M | 17.56M | 5.66M |
| NonCurrentDeferredAssets | 208.00K | 146.00K | 4.11M | |
| NetPPE | 6.42M | 8.94M | 13.45M | 5.66M |
| AccumulatedDepreciation | -7.89M | -6.15M | -3.31M | -1.42M |
| GrossPPE | 14.31M | 15.09M | 16.76M | 7.08M |
| Leases | 340.00K | 340.00K | 340.00K | 317.00K |
| ConstructionInProgress | 0.00 | 13.00K | 13.00K | 13.00K |
| OtherProperties | 13.20M | 13.56M | 15.08M | 6.27M |
| MachineryFurnitureEquipment | 775.00K | 1.17M | 1.33M | 481.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 23.82M | 80.47M | 54.59M | 29.79M |
| OtherCurrentAssets | 5.92M | 2.87M | 2.60M | 1.24M |
| PrepaidAssets | 1.24M | |||
| CashCashEquivalentsAndShortTermInvestments | 17.91M | 77.61M | 52.00M | 28.55M |
| OtherShortTermInvestments | 0.00 | 27.80M | ||
| CashAndCashEquivalents | 17.91M | 77.61M | 24.19M | 28.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -60.04M | -82.31M | -9.78M | -39.20M |
| RepaymentOfDebt | -1.43M | -1.30M | -865.00K | |
| IssuanceOfDebt | 0.00 | 35.00M | ||
| IssuanceOfCapitalStock | 2.39M | 31.24M | 0.00 | 16.33M |
| CapitalExpenditure | -123.00K | -1.13M | -4.66M | -1.87M |
| InterestPaidSupplementalData | 192.00K | 352.00K | 98.00K | |
| EndCashPosition | 17.91M | 77.61M | 24.19M | 28.55M |
| BeginningCashPosition | 77.61M | 24.19M | 28.55M | 51.79M |
| ChangesInCash | -59.70M | 53.41M | -4.36M | -23.24M |
| FinancingCashFlow | 344.00K | 62.18M | 33.32M | 15.96M |
| CashFlowFromContinuingFinancingActivities | 344.00K | 62.18M | 33.32M | 15.96M |
| NetOtherFinancingCharges | -623.00K | 32.06M | -922.00K | -366.00K |
| ProceedsFromStockOptionExercised | 4.00K | 187.00K | 106.00K | 0.00 |
| NetPreferredStockIssuance | 16.33M | |||
| PreferredStockIssuance | 16.33M | |||
| NetCommonStockIssuance | 2.39M | 31.24M | 0.00 | |
| CommonStockIssuance | 2.39M | 31.24M | 0.00 | |
| NetIssuancePaymentsOfDebt | -1.43M | -1.30M | 34.13M | |
| NetLongTermDebtIssuance | -1.43M | -1.30M | 34.13M | |
| LongTermDebtPayments | -1.43M | -1.30M | -865.00K | |
| LongTermDebtIssuance | 0.00 | 35.00M | ||
| InvestingCashFlow | -123.00K | 72.41M | -32.56M | -1.87M |
| CashFlowFromContinuingInvestingActivities | -123.00K | 72.41M | -32.56M | -1.87M |
| NetInvestmentPurchaseAndSale | 0.00 | 73.54M | -27.90M | |
| SaleOfInvestment | 0.00 | 108.00M | 63.00M | |
| PurchaseOfInvestment | 0.00 | -34.46M | -90.90M | |
| NetPPEPurchaseAndSale | -123.00K | -1.13M | -4.66M | -1.87M |
| PurchaseOfPPE | -123.00K | -1.13M | -4.66M | -1.87M |
| OperatingCashFlow | -59.92M | -81.18M | -5.12M | -37.33M |
| CashFlowFromContinuingOperatingActivities | -59.92M | -81.18M | -5.12M | -37.33M |
| ChangeInWorkingCapital | -11.95M | -5.44M | 45.20M | 1.46M |
| ChangeInOtherWorkingCapital | -1.43M | -1.05M | 47.46M | |
| ChangeInOtherCurrentLiabilities | -5.33M | -4.73M | -4.66M | -813.00K |
| ChangeInPayablesAndAccruedExpense | -2.06M | -708.00K | 3.76M | 2.02M |
| ChangeInAccruedExpense | -213.00K | -2.90M | 4.23M | 3.00M |
| ChangeInPayable | -1.85M | 2.19M | -473.00K | -974.00K |
| ChangeInAccountPayable | -1.85M | 2.19M | -473.00K | -974.00K |
| ChangeInPrepaidAssets | -3.12M | 1.05M | -1.36M | 253.00K |
| OtherNonCashItems | 5.18M | 6.85M | 6.83M | 834.00K |
| StockBasedCompensation | 3.65M | 2.32M | 275.00K | 479.00K |
| AssetImpairmentCharge | 362.00K | 0.00 | ||
| AmortizationOfSecurities | 0.00 | -709.00K | 0.00 | |
| DepreciationAmortizationDepletion | 3.35M | 2.84M | 1.89M | 682.00K |
| DepreciationAndAmortization | 3.35M | 2.84M | 1.89M | 682.00K |
| OperatingGainsLosses | -33.00K | -156.00K | 1.92M | |
| GainLossOnInvestmentSecurities | -315.00K | 1.92M | ||
| GainLossOnSaleOfPPE | -33.00K | 159.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -60.48M | -86.88M | -61.23M | -40.78M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CARM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|